Cost-effective Antiemesis

International Anesthesiology Clinics

Volumn 41, Issue 4, 2003, Pages 145-164

  Gayer, Steven ^a   Lubarsky, David Alan ^b  

^a Central Building ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; DOLASETRON MESILATE; DROPERIDOL; ONDANSETRON;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEART ARRHYTHMIA; HUMAN; INTENSIVE CARE UNIT; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; QT INTERVAL; REVIEW; TORSADE DES POINTES; TREATMENT OUTCOME;

ANTIEMETICS; HUMANS; POSTOPERATIVE NAUSEA AND VOMITING;

EID: 0142094673     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004311-200341040-00011     Document Type: Review

References (45)

1. Apfel CC, Leara E, Koivuranta M, et al. A simplified risk score for predicting nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91:693-700
2. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-System Pharm 1999; 56:729-764
3. Watcha MF, White PF. Postoperative nausea and vomiting. Anesthesiology 1992;77:162-184
4. Macario A, Weinger M, Carney S, et al. Which clinical anesthesia outcomes are important to avoid: the perspective of patients. Anesth Analg 1999;89:652-658
5. Philip BK. Patients' assessment of ambulatory anesthesia and surgery. J Clin Anesth 1992;4:355-358
6. Fox ER, Tyler LS, Beckwith MC. Antiemetics. January 14, 2002. Available at:. http://www.ashp.org/shortage/antiemetic.html. Accessed April 26, 2002
7. Lewis J. Running on empty. Drug Topics 2001;18:36-43
8. Center For Drug Evaluation and Research [online database]. Drug shortages. Available at: http://www.fda.gov/cder/drug/shortages. Accessed April 26, 2002
9. Lubarsky DA. Making it pay! July 1997. Available at: http://www.anesthesiaweb.com/protected/lit/dl-97jul-russel.shtml. Accessed April 27, 2002
10. Russell LB, Gold MR, Seigel JE, et al. The role of cost effectiveness analysis in health and medicine. JAMA 1996;276:1172-1177
11. Lubarsky DA. Understanding cost analysis: part I. A practitioner's guide for economic evaluations. J Clin Anesth 1995;7:519-521
12. Lubarsky DA, Glass PS, Ginsberg B, et al. The successful implementation of pharmaceutical practice guidelines. Analysis of associated outcomes and cost savings. SwiPE Group. Systematic withdrawal of perioperative expenses. Anesthesiology 1997;86:1145-1160
13. Dexter F, Tinker JH. Analysis of strategies to decrease postanesthetic care unit costs. Anesthesiology 1995;82:94-101
14. Fazi L, Watcha MF. The economics of new anaesthetic drugs: should we take the Rolls Royce or the bicycle today? [Editorial] Paediatr Anaesth 1999;9:181-185
15. Watcha MF, White PF. Economics of anesthetic practice. 1997;86:1170-1196
16. Gold BS, Kitz DS, Lecky JH, et al. Unanticipated admission to the hospital following ambulatory surgery. JAMA 1989;262:3008-3010
17. Tramer MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiol Scand 2001;45:4-13
18. Gan TJ, Sloan F, Dear GL, et al. How much are patients willing to pay to avoid post-operative nausea and vomiting? Anesth Analg 2001;92:393-400
19. Mark DH. Visualizing cost-effectiveness analysis. JAMA 2002;287:2428-2429
20. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258
21. Fisher DM. Surrogate outcomes: meaningful not! [Editorial] Anesthesiology 1999;90: 355-356
22. Gan TJ, Lubarsky DA. Cost effectiveness ratio: an often misunderstood term [letter]. Anesth Analg 1999;88:1191-1192
23. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analysis. JAMA 1996;276:1339-1341
24. Tramer MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part II. Recommendations for prevention and treatment, and research agenda. Acta Anesthesiol Scand 2001;45:14-19
25. Gan TJ, Lubarsky DA. Response to letter to the editor. Anesth Analg 2001;93:515
26. Parkin M. Economics. 3rd ed. Boston, MA: Addison Wesley; 1996
27. Tversky A, Kahneman D. Judgment under uncertainty: heuristics and biases. Science 1974;185:1124-1131
28. Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999;91:109-118
29. Tang J, Watcha MF, White PF. A comparison of costs and efficacy of ondansetron and droperidol as prophylactic antiemetic therapy for elective outpatient gynecologic procedures. Anesth Analg 1996;83:304-313
30. Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology 2000;92:958-967
31. McCormick CG. FDA alert: current FDA report on droperidol status and basis for "black box" warning. ASA Newsletter 2002;66:19-20
32. Akorn Pharmaceuticals. Dear health care professional. December 4, 2001. Available at: http://www.fda.gov/medwatch/safety/2001/inapsine.htm. Accessed April 25, 2002
33. Tang J, Wang B, White PF, et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998;86:274-282
34. Zarate E, Watcha MF, White PF, et al. A comparison of costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg 2000;90:1352-1358
35. Scuderi PE, James RL, Harris L, et al. Antiemetic prophylaxis does not improve outcomes after outpatient surgery when compared to symptomatic treatment. Anesthesiology 1999;90:360-371
36. Scuderi PE, James RL, Harris L, et al. Multimodal antiemetic management prevents early postoperative vomiting after outpatient laparoscopy. Anesth Analg 2000;91:1408-1414
37. McKenzie R, Tantisira B, Karambelkar DJ, et al. Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting. Anesth Analg 1994;79:961-964
38. Splinter WM, Roberts DJ. Dexamethasone decreases vomiting by children after tonsillectomy. Anesth Analg 1996;83:913-916
39. Fortney JT, Gan TJ, Graczyk S, et al. A comparison of the efficacy, safety and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. Anesth Analg 1998;86:731-738
40. Subramaniam B, Madan R, Sadhasivam S, et al. Dexamethasone is a cost-effective alternative to ondansetron in preventing PONV after paediatric strabismus repair. Br J Anaesth 2001;86:84-89
41. Greif R, Laciny S, Rapf B, et al. Supplemental oxygen reduces the incidence of postoperative nausea and vomiting. Anesthesiology 1999;91:1246-1252
42. Henzi I, Walder B, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anesth 2000;47:537-551
43. Wang JJ, Ho ST, Tzeng JI, et al. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. Anesth Analg 2000;91:136-139
44. Frighetto L, Loewen PS, Dolman J, et al. Cost-effectiveness of prophylactic dolasetron or droperidol versus rescue therapy in the prevention of PONV in ambulatory gynecologic surgery. Can J Anesth 1999;46:536-543
45. Jellish WS, Zuhair T, Fluter E. Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures. J Clin Anesth 1997;9:451-456